King Pharmaceuticals has notified the FDA that it will stop manufacturing Cortisporin ophthalmic suspension (neomycin/polymyxin B sulfates/hydrocortisone). Many factors, including the company’s understanding of current medical therapy and the availability of alternative therapies, played a role in the decision to discontinue this product.

Cortisporin ophthalmic suspension is indicated for steroid-responsive ocular inflammation associated with bacterial infection.

For more information call (800) 776-3637 or visit www.fda.gov/cder/drug/shortages/default.htm#Cortisporin.